Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for myeloma patients: drug combo aims to keep cancer at bay

NCT ID NCT07555938

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests whether adding the experimental drug cevostamab to standard medications (pomalidomide and dexamethasone) works better than current treatments for multiple myeloma. About 380 adults whose cancer came back after 1 to 3 prior therapies will take part. The goal is to see if the combination can make the cancer disappear completely or delay its return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 380 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jan 2033

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to start of administration of study treatment. * Individuals with ECOG Performance Status of 2 solely due to local symptoms of myeloma (e.g., pain) are eligible * MM diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria * Received one to three lines of prior therapy that included at least two consecutive cycles of either of the following: A regimen containing an anti-CD38 therapy, a regimen containing lenalidomide * Participants must have measurable disease during screening Exclusion Criteria: * Known history of amyloidosis (e.g., positive Congo Red stain or equivalent in tissue biopsy or documented within serum amyloid P component scan) * Plasma cell leukemia or circulating plasma cell count exceeding 500 cells/liter (L) or 5% of the peripheral blood white cells * GI disease that might significantly alter absorption of oral drugs * Participants must not have any ongoing CNS disease or non-secretory myeloma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    40 sites in 11 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alexandras General Hospital of Athens

    RECRUITING

    Athens, 11528, Greece

  • Anticancer Hospital of Thessaloniki " Theagenio"

    RECRUITING

    Thessaloniki, 540 07, Greece

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

  • Asst Papa Giovanni Xxiii

    RECRUITING

    Bergamo, Lombardy, 24127, Italy

  • Auxilio Mutuo Cancer Center

    RECRUITING

    San Juan, 917, Puerto Rico

  • Chaim Sheba Medical Center

    RECRUITING

    Ramat Gan, 5266200, Israel

  • Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin

    RECRUITING

    Berlin, 12200, Germany

  • Chonnam National University Hwasun Hospital

    RECRUITING

    Jeollanam-do, 58128, South Korea

  • City of Hope - Lennar Foundation Cancer Center

    RECRUITING

    Irvine, California, 92618, United States

  • City of Hope National Medical Center

    RECRUITING

    Duarte, California, 91010-3012, United States

  • Clinica Universitaria de Navarra

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Dokkyo Medical University Saitama Medical Center

    RECRUITING

    Saitama, 343-8555, Japan

  • Emory University Hospital Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

  • Evangelismos General Hospital of Athens

    RECRUITING

    Athens, 106 76, Greece

  • Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists

    RECRUITING

    Winston-Salem, North Carolina, 27103, United States

  • Gunma University Hospital

    RECRUITING

    Gunma, 371-8511, Japan

  • HELIOS Klinikum Bad Saarow

    RECRUITING

    Bad Saarow, 15526, Germany

  • Hamilton Health Sciences - Juravinski Cancer Centre

    RECRUITING

    Hamilton, Ontario, L8V 1C3, Canada

  • Hospital Clinic i Provincial de Barcelona

    RECRUITING

    Barcelona, 08036, Spain

  • Hospital Clinico Universitario de Salamanca

    RECRUITING

    Salamanca, 37007, Spain

  • Hospital General Universitario Gregorio Marañon

    RECRUITING

    Madrid, 28009, Spain

  • Hyogo Medical University Hospital

    RECRUITING

    Hyōgo, 663-8501, Japan

  • IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori"

    RECRUITING

    Meldola, Emilia-Romagna, 47014, Italy

  • Istituto Clinico Humanitas

    RECRUITING

    Rozzano, Lombardy, 20089, Italy

  • MedStar Washington Hospital Center MedStar Georgetown Cancer Institute

    RECRUITING

    Washington D.C., District of Columbia, 20010, United States

  • Nagoya City University Hospital

    RECRUITING

    Aichi, 467-8602, Japan

  • National Hospital Organization Okayama Medical Center

    RECRUITING

    Okayama, 701-1192, Japan

  • Novant Health Cancer Institute

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • Rambam Health Care Campus

    RECRUITING

    Haifa, 31096, Israel

  • SP ZOZ Szpital Uniwersytecki w Krakowie-Jakubowskiego 2;Oddzial Kliniczny Hematologii

    RECRUITING

    Krakow, Lesser Poland Voivodeship, 30-688, Poland

  • Samsung Medical Center

    RECRUITING

    Seoul, 06351, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • Seoul St Mary's Hospital

    RECRUITING

    Seoul, 06591, South Korea

  • The Cancer Institute Hospital of JFCR

    RECRUITING

    Tokyo, 135-8550, Japan

  • Toyohashi Municipal Hospital

    RECRUITING

    Toyohashi, Aichi-ken, 441-8570, Japan

  • TriHealth Cancer and Blood Institute

    RECRUITING

    Cincinnati, Ohio, 45220, United States

  • UKSH, Campus Kiel

    RECRUITING

    Kiel, 24105, Germany

  • University Hospital Kyoto Prefectural University of Medicine

    RECRUITING

    Kyoto, 602-8566, Japan

  • Uniwersyteckie Centrum Kliniczne

    RECRUITING

    Gda?sk, 80-214, Poland

  • Yamagata University Hospital

    RECRUITING

    Yamagata, 990-9585, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.